Comparative Pharmacology
Head-to-head clinical analysis: CARDIOGRAFIN versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOGRAFIN versus VISIPAQUE 320.
CARDIOGRAFIN vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardiografin is an ionic, high-osmolar iodinated contrast agent used for radiographic imaging. It enhances contrast by attenuating X-rays, primarily due to the iodine content. It distributes in the extracellular space and is excreted unchanged by glomerular filtration.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Adult: 50-100 mL of CARDIOGRAFIN (diatrizoate meglumine and diatrizoate sodium) 76% intravenously as a bolus or rapid infusion. For cardiac ventriculography, 40-50 mL into the left ventricle. For coronary arteriography, 5-10 mL selective injection per artery.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life ~2 hours (normal renal function). May be prolonged to >20 hours in severe renal impairment (e.g., CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Primarily renal (glomerular filtration) with >90% of dose excreted unchanged in urine within 24 hours; less than 1% biliary/fecal; negligible metabolism.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent